Anyone ever get a shedding phase on RU58441 Chat 10/5/2024
The user experienced increased hair shedding after using RU58841 for two months, but found relief from scalp itchiness. Other users shared similar shedding experiences and discussed side effects like joint pain, while also mentioning the use of finasteride and minoxidil.
View this post in the Community ā
Similar Community Posts Join
5 / 5 resultscommunity Iām on a crazy hairloss stack and Iām still losing hair and not experiencing any regrowth. What is going on?
The user is using a combination of hair loss treatments including finasteride, stemoxydine, oral minoxidil, RU58841, dermastamping, ketoconazole shampoo, collagen, Viviscal, and biotin, and has improved their diet. Despite these efforts, they are still experiencing hair shedding and scalp itchiness, and are considering increasing their minoxidil dosage or starting dutasteride.
community My experience with fin, dut, ru, and minoxidil. 25M (around 2 years of fin, 1 year ru, 4 years minoxidil, 1.5 years dut)
A 25-year-old male experienced hair improvement using finasteride, minoxidil, and RU58841, but saw hair thinning after switching to dutasteride and stopping RU. He plans to continue dutasteride for six months while considering adding RU back due to its positive effects on scalp itch and inflammation.
community KX-826 Phase 3 Results Are Out
KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.
community Creatine and hair loss...you're not crazy.
Creatine may increase DHT levels, potentially causing hair loss in some people, though experiences vary. Treatments like finasteride or minoxidil are suggested to manage potential hair loss.
community Is there a consensus on RU these days? Pyril turned out to be a bust right?
The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.
Related Research
6 / 6 results
research Potential targets in the discovery of new hair growth promoters for androgenic alopecia
This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.
research Therapeutic strategies for treating hair loss
This article discusses the need for rational strategies in developing hair loss drugs targeting specific events in hair follicle cycling, reporting no clinical findings but emphasizing the importance of understanding molecular controls.
research Real-time in vivo structure-function study of scalp hair cycles: an experimental approach for monitoring living hair roots with a 20-year follow-up
In this study, after long-term observation of human scalp hair follicles over 16 years, the researchers found that a topical 5% minoxidil solution could stimulate hair regrowth after a period of dormancy, though with reduced growth rates and hair diameter.
research Androgenetic alopecia
This article discusses androgenetic alopecia and reports no new clinical results.
research Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment
This review article examines current drugs for androgenetic alopecia, focusing on their mechanisms and clinical efficacy, noting that while finasteride and minoxidil are commonly approved treatments, new drugs targeting different pathogenic pathways have emerged, offering a broader understanding and reference for AGA treatment options.
research Treatments for Androgenetic Alopecia and Alopecia Areata
This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.